{"entity":{"id":"paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023","kind":"paper","name":"A click-activated MMAE prodrug switched on by an injected biopolymer or by a HER2-binding antibody fragment","aka":["Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents"],"tldr":"A mouse study showing the same chemistry can be steered by a tumour-seeking protein instead of an injection, and can switch on MMAE, a toxin too harsh to give on its own.","summary":"Shasqi extends its platform in two directions. The drug is monomethyl auristatin E (MMAE), modified with a trans-cyclooctene to form the prodrug SQP22, which reduced its cytotoxicity in cells and in animals. The activator is either the tetrazine-modified hyaluronate SQL70 injected into the tumour, or SQT01, a tetrazine-modified HER2-targeting antigen-binding fragment given by infusion.\n\nSQP22 with SQL70 had anti-tumour effects in the Karpas 299 and RENCA mouse models and showed that the click reaction was required for activation. SQP22 with SQT01 had anti-tumour effects in the HER2-positive NCI-N87 xenograft, showing that activation at the tumour could be achieved with both components given systemically. Toxicity was limited to transient myelosuppression and moderate loss of body weight.","asOf":"2026-11-16","links":[{"label":"ACS Cent Sci 2023","url":"https://doi.org/10.1021/acscentsci.3c00365"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37521794/"},{"label":"Europe PMC (free full text)","url":"https://europepmc.org/article/MED/37521794"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["click-activated-prodrugs"],"targets":["her2"],"drugs":[],"companies":["shasqi"],"institutions":[],"pathways":[],"terms":["mmae"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo (company site, ClinicalTrials.gov v2, Crossref, Europe PMC, NIH RePORTER)","editedOn":"2026-11-16"},"journal":"ACS Central Science","year":2023,"doi":"10.1021/acscentsci.3c00365","pmid":"37521794","authors":"McFarland JM, Alečković M, Coricor G, et al.","paperType":"basic","findings":["Capping MMAE with a trans-cyclooctene (SQP22) reduced its cytotoxicity in vitro and in vivo.","SQP22 with intratumoral SQL70 showed anti-tumour effects in Karpas 299 and RENCA models.","SQP22 with the systemically given HER2-binding fragment SQT01 showed anti-tumour effects in the HER2-positive NCI-N87 xenograft."],"whatItMeans":"It is the published basis for the antigen-targeted programmes on Shasqi's pipeline, which no longer need a tumour that can be injected. None of these has been tested in people.","caveats":["Mouse models only; the abstract gives no effect sizes.","Funded and authored by Shasqi."],"changedPractice":false},"route":"/key-papers/paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023/","neighbours":{"technology":[{"id":"click-activated-prodrugs","kind":"technology","name":"Click-activated prodrugs (bioorthogonal drug activation in the body)","route":"/technologies/click-activated-prodrugs/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/"}],"term":[{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/"}]}}